Introducing
v2vmedtech, inc.

Transcatheter edge-to-edge repair (TEER) has been established as the leading therapy for minimally invasive mitral valve insufficiency and is rapidly being adopted for the tricuspid valve.

v2vmedtech, inc. is an early-stage medical device company pioneering an innovative TEER system aimed at significant improvements in versatility over current TEER devices to expand the treatable patient population and improve outcomes in repair treatment both for the tricuspid and mitral valves.